Mini-Hyper-CVD Protocol
Mini-hyper-CVD is a dose-reduced modification of the original hyper-CVAD regimen, specifically designed for older adults or patients who cannot tolerate full-intensity chemotherapy, consisting of reduced doses of cyclophosphamide, vincristine, doxorubicin (often omitted), and dexamethasone alternating with reduced-dose methotrexate and cytarabine. 1
Core Components and Dosing
The mini-hyper-CVD regimen differs from standard hyper-CVAD through several key dose reductions:
- Dexamethasone: 50% dose reduction from standard hyper-CVAD
- Methotrexate: 75% dose reduction from standard dosing
- Cytarabine: Reduced to 0.5 g/m² given every 12 hours on days 2 and 3 (compared to higher doses in standard regimen)
- Anthracycline (doxorubicin): Typically omitted entirely in the mini version 1
- Cyclophosphamide and vincristine: Reduced doses compared to standard hyper-CVAD
Clinical Applications
Primary Indication: Older Adults with ALL
Mini-hyper-CVD was developed specifically for adults with acute lymphoblastic leukemia (ALL) who are older (typically ≥60 years) or have significant comorbidities that preclude standard-intensity chemotherapy 1. The regimen addresses the reality that traditional chemotherapy backbones based on vincristine, corticosteroids, and anthracyclines have limited utility in this population due to treatment-related toxicities.
Combination with Novel Agents
The reduced-intensity backbone allows safe incorporation of targeted therapies:
With Inotuzumab Ozogamicin (InO): In a phase II study of 52 patients (median age 68 years) with newly diagnosed Ph-negative ALL, mini-hyper-CVD combined with InO achieved a 2-year progression-free survival of 59%. InO was administered on day 3 of the first 4 courses at 1.3-1.8 mg/m² for cycle 1, followed by 1.0-1.3 mg/m² for subsequent cycles 1.
With Venetoclax: A phase 1/2 trial demonstrated that mini-hyper-CVD plus venetoclax (400 mg daily on days 1-14 in cycle 1, then days 1-7 in consolidation) achieved a composite CR/CRi rate of 57% in heavily pretreated relapsed/refractory ALL patients 2.
Dose-dense regimen with InO and Blinatumomab: Recent data shows that earlier administration of blinatumomab with mini-hyper-CVD and InO resulted in rapid MRD negativity, with 91% achieving next-generation sequencing MRD negativity at 10⁻⁶ sensitivity in frontline patients 3.
Treatment Schedule
The regimen alternates between two different chemotherapy combinations, similar to standard hyper-CVAD but with reduced doses. Maintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, prednisone) is typically given for 3 years following induction and consolidation 1.
Key Toxicities and Monitoring
Critical Safety Concerns
Sinusoidal Obstruction Syndrome (SOS): When combined with inotuzumab ozogamicin, SOS occurred in 8% of patients—a potentially fatal complication requiring vigilant monitoring 1.
Infections: The most common grade ≥3 adverse event, occurring in 77% of patients in the venetoclax combination study, with febrile neutropenia in 18% 2. Prolonged thrombocytopenia occurred in 81% of patients receiving mini-hyper-CVD with InO 1.
Hyperglycemia: Grade 3-4 hyperglycemia occurred in 54% of patients, related to dexamethasone component 1.
Agent-Specific Toxicities to Monitor
From cyclophosphamide 4:
- Hemorrhagic cystitis: Requires aggressive hydration with forced diuresis and frequent bladder emptying; mesna prophylaxis should be used
- Cardiotoxicity: Monitor patients with pre-existing cardiac disease or risk factors
- Pulmonary toxicity: Can develop years after treatment
- Veno-occlusive liver disease: Particularly in patients with hepatic dysfunction
From vincristine 5:
- Neurotoxicity: Dose-limiting toxicity requiring careful monitoring
- Poor CNS penetration: Does not prevent CNS leukemia
Clinical Outcomes
In older adults with newly diagnosed Ph-negative ALL (median age 68 years), mini-hyper-CVD with InO demonstrated:
- 2-year progression-free survival: 59% (95% CI, 43%-72%)
- High rate of MRD negativity after induction 1
For relapsed/refractory ALL with venetoclax combination:
- CR/CRi rate: 57%
- Median overall survival: 7.1 months
- 1-year overall survival: 29% 2
Important Caveats
Completion rates are suboptimal: Even with dose reductions, only 65% of patients completed six cycles in some studies, with 81% experiencing unplanned hospital admissions 6. This underscores that "mini" does not mean "easy"—these patients require intensive supportive care.
Not curative as monotherapy: For older adults with multiple comorbidities who cannot receive intensive therapy, mini-hyper-CVD and similar low-intensity regimens are unlikely to generate cure but can palliate disease and extend survival 1.
Fertility and contraception: Despite dose reduction, cyclophosphamide can cause irreversible sterility. Verify pregnancy status before starting; females need contraception during treatment and for 1 year after, males for 4 months after completion 4.